Table 2 Association between intratumoral lymphatic vessel density and clinicopathologic variables in oral squamous cell carcinomas. A.C.Camargo Cancer Hospital. São Paulo, Brazil
Variable | Intratumoral lymphatic vessel density | |||||
|---|---|---|---|---|---|---|
Sequential analysis | p value | Hot spot evaluation | p value | |||
Low | High | Low | High | |||
Gender | ||||||
Male Female | 43 (86.0%) 07 (14.0%) | 25 (67.6%) 12 (32.4%) | 0.040 | 38 (82.6%) 08 (17.4%) | 30 (73.2%) 11 (26.8%) | 0.288 |
Ethnic group | ||||||
White Not white | 47 (94.0%) 03 (6.0%) | 33 (89.2%) 04 (10.8%) | 0.452 | 44 (95.7%) 02 (4.3%) | 36 (87.8%) 05 (12.2%) | 0.247 |
Age | ||||||
≤ 59 years > 59 years | 28 (56.0%) 22 (44.0%) | 17 (45.9%) 20 (54.1%) | 0.354 | 25 (54.3%) 21 (45.7%) | 20 (48.8%) 21 (51.2%) | 0.604 |
Tobacco# | ||||||
No Yes | 04 (8.5%) 43 (91.5%) | 05 (14.7%) 29 (85.3%) | 0.481 | 05 (11.6%) 38 (88.450 | 04 (10.5%) 34 (89.5%) | 1.000 |
Alcohol# | ||||||
No Yes | 08 (17.0%) 39 (83.0%) | 07 (20.6%) 27 (79.4%) | 0.683 | 08 (18.6%) 35 (81.4%) | 07 (18.4%) 31 (81.6%) | 0.983 |
Tumor site | ||||||
Tongue Floor of mouth | 34 (68.0%) 16 (32.0%) | 26 (70.3%) 11 (29.7%) | 0.821 | 31 (67.4%) 15 (32.6%) | 29 (70.7%) 12 (29.3%) | 0.737 |
T stage | ||||||
T1 T2 | 19 (38.0%) 31 (62.0%) | 09 (24.3%) 28 (75.7%) | 0.177 | 18 (39.1%) 28 (60.9%) | 10 (24.4%) 31 (75.6%) | 0.142 |
Local recurrence | ||||||
No Yes | 41 (82.0%) 09 (18.0%) | 31 (83.8%) 06 (16.2%) | 0.828 | 37 (80.4%) 09 (19.6%) | 35 (85.4%) 06 (14.6%) | 0.543 |
Regional recurrence | ||||||
No Yes | 45 (90.0%) 05 (10.0%) | 28 (75.7%) 09 (24.3%) | 0.072 | 42 (91.3%) 04 (8.7%) | 31 (75.6%) 10 (24.4%) | 0.047 |
Lymphatic embolization | ||||||
No Yes | 38 (76.0%) 12 (24.0%) | 24 (64.9%) 13 (35.1%) | 0.257 | 36 (78.3%) 10 (21.75) | 26 (63.4%) 15 (36.6%) | 0.127 |
Blood embolization | ||||||
No Yes | 43 (86.0%) 07 (14.0%) | 32 (86.5%) 05 (13.5%) | 0.948 | 39 (84.8%) 07 (15.2%) | 36 (87.8%) 05 (12.2%) | 0.683 |
Perineural infiltration | ||||||
No Yes | 26 (52.0%) 24 (48.0%) | 17 (45.9%) 20 (54.1%) | 0.577 | 25 (54.3%) 21 (45.7%) | 18 (43.9%) 23 (56.1%) | 0.331 |
Muscular infiltration | ||||||
No Yes | 11 (22.0%) 39 (780%) | 05 (13.5%) 32 (86.5%) | 0.312 | 10 (21.7%) 36 (78.3%) | 06 (14.6%) 35 (85.4%) | 0.393 |
Salivary gland infiltration | ||||||
No Yes | 34 (68.0%) 16 (32.0%) | 24 (64.9%) 13 (35.1%) | 0.759 | 33 (71.7%) 13 (28.3%) | 25 (61.0%) 16 (39.0%) | 0.288 |
Lymph-nodal status# | ||||||
pN0 pN + | 32 (84.2%) 06 (15.8%) | 18 (69.2%) 08 (30.8%) | 0.155 | 29 (82.9%) 06 (17.1%) | 21 (72.4%) 08 (27.6%) | 0.314 |
Malignancy grading | ||||||
More differentiated Less differentiated | 38 (76.0%) 12 (24.0%) | 31 (83.8%) 06 (16.2%) | 0.376 | 34 (73.9%) 12 (26.1%) | 35 (85.4%) 06 (14.6%) | 0.188 |